- Open Access
Redox/NIR dual-responsive MoS2 for synergetic chemo-photothermal therapy of cancer
Journal of Nanobiotechnology volume 17, Article number: 78 (2019)
The construction of a multifunctional drug delivery system with a variety of advantageous features, including targeted delivery, controlled release and combined therapy, is highly attractive but remains a challenge.
In this study, we developed a MoS2-based hyaluronic acid (HA)-functionalized nanoplatform capable of achieving targeted delivery of camptothecin (CPT) and dual-stimuli-responsive drug release. HA was connected to MoS2 via a disulfide linkage, forming a sheddable HA shell on the surface of MoS2. This unique design not only effectively prevented the encapsulated CPT from randomly leaking during blood circulation but also significantly accelerated the drug release in response to tumor-associated glutathione (GSH). Moreover, the MoS2-based generated heat upon near-infrared (NIR) irradiation could further increase the drug release rate as well as induce photothermal ablation of cancer cells. The results of in vitro and in vivo experiments revealed that MoS2–SS–HA–CPT effectively suppressed cell proliferation and inhibited tumor growth in lung cancer cell-bearing mice under NIR irradiation via synergetic chemo-photothermal therapy.
The as-prepared MoS2–SS–HA–CPT with high targeting ability, dual-stimuli-responsive drug release, and synergistic chemo-photothermal therapy may provide a new strategy for cancer therapy.
Cancer has already been proven to be a major threat to human health, with more than eight million cancer-related deaths each year worldwide . Chemotherapy is still the most common approach to cancer therapy, and approximately 80 different anticancer drugs are used in clinical treatment . Unfortunately, these conventional anticancer drugs suffer numerous limitations, including drug resistance, nonspecific distribution, toxic side effects, and hydrophobicity [3, 4]. Therefore, numerous nanosized drug delivery systems with unique properties, such as active targeting, enhanced permeation and retention (EPR) effect, and stimuli-responsive drug release have been constructed to overcome these shortcomings [5,6,7,8,9]. In particular, multifunctional nanomaterials for combined therapy have the potential to realize great therapeutic effects on cancer, one of which is the ability to combine chemotherapy and photothermal therapy [10, 11]. As a minimally invasive or noninvasive approach to cancer treatment, photothermal therapy, which utilizes absorbed NIR light to generate hyperthermia for tumor ablation, has attracted widespread attention . To date, several nanomaterials with strong NIR absorbance have been used as photothermal agents for cancer therapy, such as gold nanorods, CuS particles, carbon nanotubes, and reduced graphene [13,14,15,16]. More importantly, these nanomaterials are used to develop photothermally controlled drug release systems, which can reduce drug doses and avoid side effects. Therefore, integrating photothermal therapy and chemotherapy into one nanoplatform appears to be an effective therapeutic approach to cancer therapy.
Molybdenum disulfide (MoS2), a kind of two-dimensional (2D) transition metal dichalcogenide (TMDC), has been widely investigated for applications in electronic devices and catalysis because of its unique properties [17, 18]. Recently, several research teams have explored MoS2 for biomedical applications, particularly in drug and gene delivery . Additionally, the high NIR absorbance of TMDCs has prompted research on photothermal therapy with MoS2 [20,21,22,23,24,25,26,27,28,29]. However, the application of MoS2 in biomedicine is limited because of its severe agglomeration in a physiological environment . To address this problem, several polymers have been used to enhance the physiological stability of MoS2 [21, 29]. HA, a water-soluble mucopolysaccharide consisting of N-acetyl-d-glucosamine and d-glucuronic acid, exhibits excellent biodegradability, biocompatibility and nonimmunogenicity . In addition, HA can specifically bind the cluster determinant 44 (CD44), which is overexpressed on the surface of various tumor cells [31, 32]. Because of the unique properties of HA, Dong et al. recently developed a HA-decorated MoS2 nanoplatform with high physiological stability as a drug carrier for the targeted delivery of doxorubicin . Unfortunately, HA can form a shell on the surface of MoS2 nanosheets after HA coating, similar to graphene oxide (GO), and this shell can restrict the release of the loaded drug, which seriously reduces the therapeutic efficacy of the nanosheets . To achieve rapid intracellular drug release, stimuli-responsive nanoplatforms capable of adapting to the tumor microenvironment (e.g., temperature, pH, and redox conditions) should be established. Among these stimuli, redox as a stimulus is especially appealing because of the great difference in the concentration of GSH between the interior (10 mM) and exterior (ca. 10 μM) of tumors [35, 36]. Furthermore, tumor tissues are highly hypoxic, with at least fourfold more GSH than normal tissues [37, 38]. Hence, the significant difference in GSH concentration can be used to remove the diffusion barrier caused by HA.
In this study, we developed a MoS2-based HA-functionalized drug delivery system (MoS2–SS–HA–CPT) that facilitated the delivery of CPT based on active targeting, responded to dual stimuli (GSH and NIR light) for rapid intracellular drug release, and achieved synergetic chemo-photothermal therapy of cancer. In brief, single-layer MoS2 nanosheets obtained by chemical exfoliation were conjugated with thiolated HA by forming disulfide bonds (Fig. 1a). Then, CPT, a hydrophobic broad-spectrum anticancer agent, was loaded onto the MoS2–SS–HA nanosheets by hydrophobic interactions, forming a drug delivery system. Cellular uptake of HA-grafted MoS2 nanosheets and intracellular dual-stimuli-responsive drug release were evaluated in adenocarcinoma human alveolar basal epithelial cells (A549). Finally, a series of in vitro and in vivo studies were carried out to study the synergetic chemo-photothermal therapy of cancer.
HA [molecular weight (MW) = 21 kDa] was purchased from Fureda Biological Technology Co., Ltd. (Jinan, China). MoS2 crystals (> 99.5%) were purchased from Muke Nano Science and Technology Co., Ltd. (Nanjing, China). CPT (> 95%), dithiothreitol (> 99%,DTT), and cystamine hydrochloride (> 96%) were acquired from Sigma-Aldrich (St Louis, MO, USA). N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC·HCl) and N-hydroxysuccinimide (98%, NHS) were obtained from Aladdin Biochemical Technology Co., Ltd. (Shanghai, China). Dulbecco’s modified eagle medium (DMEM) and Kaighn’s modification of Ham’s F-12 (F-12K) medium were purchased from Life Technologies GmbH (Darmstadt, Germany). All other reagents were purchased from J&K Scientific Ltd. (Shanghai, China) and used without further purification. Amicon Ultra-15 centrifugal filters (molecular-weight cutoff (MWCO) = 100 kDa) were purchased from Millipore Corp. (Massachusetts, USA).
Preparation of sulfhydrylated HA
Sulfhydrylated HA was synthesized according to the method reported in the literature . In brief, HA (100 mg) was dissolved in 10 mL of phosphate-buffered saline (PBS, pH 7.4) followed by addition of 24 mg of EDC·HCl and 18 mg of NHS. After 1 h of reaction, the activated HA was added dropwise into 10 mL of cysteamine hydrochloride in PBS (56 mg/mL) and stirred overnight. The reaction mixture was washed with deionized water several times by ultrafiltration (3000 rpm, Sorvall ST 16R, Thermo Scientific) to remove residual EDC, NHS and cysteamine hydrochloride. Subsequently, the pH of the resulting solution was adjusted to 8.5 by addition of NaOH aqueous solution (2 M), and DTT (200 mg) was added to the reaction mixture to cleave the disulfide bond in the conjugated cystamine. After 24 h of stirring under a N2 atmosphere, the reaction solution was dialyzed (MWCO = 8–14 kDa) against deionized water at pH 3.5 for 2 days. Finally, the purified solution was lyophilized to obtain HA–SH as a white foam (yield 82%).
Preparation of HA-grafted MoS2 via a disulfide linkage
The preparation of MoS2 nanosheets started from MoS2 crystals by the Morrison method . Functionalization of the MoS2 with HA is quite easy to achieve because the freely exposed sulfur on MoS2 can easily bind to other sulfur-containing moieties by forming disulfide bonds [41, 42]. Briefly, 25 mg of HA–SH was added to 0.5 mg/mL MoS2 nanosheets aqueous solution (10 mL). After sonication for 30 min and stirring for 24 h, the mixture solution was dialyzed (MWCO = 100 kDa) against deionized water for 3 days to remove excess HA–SH, and the obtained MoS2–SS–HA was stored at 4 °C for further use.
Fourier transform infrared (FT-IR) spectra were obtained using a FT-IR spectrometer (Tensor 27, Bruker). Ultraviolet–visible–near infrared (UV–vis–NIR) spectra were measured using a UV–vis spectrophotometer (UV-2700, Shimadzu). Thermogravimetric analysis (TGA) was performed under an argon atmosphere using a thermal analysis system (STA449C, NETZSCH). Atomic force microscopy (AFM) images were captured using a scanning probe (Multimode 8, Bruker). Zeta-potential and dynamic light scattering (DLS) analyses were carried out using a Zetasizer (Nano ZS 90, Malvern). The temperature curves were recorded using a thermal camera (AX315, FLIR).
For preparation of CPT-loaded MoS2 nanosheets, 2 mL of CPT in dimethyl sulfoxide (DMSO, 0.2 mg/mL) was added to an equal volume of MoS2–SS–HA aqueous dispersion (0.1 mg/mL). After stirring for 24 h, the excess CPT precipitated as a solid, was removed by centrifugation at 5000 rpm for 20 min. The supernatant was filtered through a 0.45-μm filter and washed several times with PBS via ultrafiltration (3000 rpm) to remove the small amount of solubilized CPT. The drug loading capacity of MoS2–SS–HA was determined by UV–vis spectroscopy at 365 nm.
Dual-stimuli-responsive drug release
MoS2–SS–HA–CPT were enclosed in a dialysis bag and immersed in 20 mL of PBS containing DMSO (5% v/v, pH 7.4) with or without GSH, followed by placement in a shaking bed at a speed of 100 rpm. At the desired time points, a portion of the samples were irradiated under an 808-nm laser at 1 W/cm2 for 10 min. For each measurement, 0.2 mL of dialysis solution was removed and replaced with the same volume of the corresponding buffer. The CPT amount was determined by the absorption peak at 365 nm via UV–vis spectroscopy.
Female BALB/C nude mice (age, 6–8 weeks; body weight, 20–25 g) were purchased from Slac Animal Inc. (Shanghai, China). Mice were housed in clean, pathogen-free plastic cages with controlled temperature (26 °C), humidity (55%), filtered atmosphere and a 12 h light/dark cycle. Mice were provided aseptic food and water ad libitum.
Red blood cells (RBCs) from a healthy nude mouse were separated from serum by centrifugation at 2000 rpm for 10 min, washed several times with PBS, and then diluted with PBS. Various concentrations of MoS2–SS–HA in PBS were added to RBC solutions, which were then shaken (100 rpm) at 37 °C for 2 h. After high-speed centrifugation (15,000 rpm for 10 min), the absorbance of the supernatant from each sample at 541 nm was measured via UV–vis spectroscopy. In this experiment, solutions of RBCs mixed with deionized water and PBS alone were employed as the positive and negative controls, respectively. The hemolysis percent was calculated as hemolysis percent (%) = (Atreated − Anegative)/(Apositive − Anegative) × 100%.
A549 and human embryonic lung fibroblasts (HELF) cells were purchased from the Cell Resource Center of Shanghai Institute for Biological Sciences (Chinese Academy of Sciences). A549 and HELF cells were cultured in F-12 K medium and DMEM medium, respectively. The medium was supplemented with 10% (v/v) fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin. The cells were all maintained at 37 °C in a humidified atmosphere with 5% CO2.
Cytotoxicity of MoS2–SS–HA in vitro
In the current work, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays were used to investigate the cytotoxicity of MoS2–SS–HA in vitro. In brief, A549 and HELF cells were seeded into 96-well cell culture plates at 5 × 103/well and 6 × 103/well, respectively, and incubated for 24 h. The cells were washed with PBS and treated with various concentrations of the material for 48 h. After these treatments, a MTT assay was carried out to determine cell viability.
Cellular uptake of HA-grafted MoS2 nanosheets
In this experiment, rhodamine B (RB) was employed as a fluorescent probe. Briefly, 1 mL of RB aqueous solution (1 mg/mL) was mixed with 4 mL of MoS2–SS–HA in deionized water (1 mg/mL) and stirred at room temperature for 24 h. Excess RB was removed by ultrafiltration (3000 rpm), and the resulting fluorescent-labeled MoS2–SS–HA was stored at 4 °C for future use.
A549 and HELF cells were seeded in confocal dishes at densities of 3 × 105 and 4 × 105 cells/dish, respectively, and allowed to grow for 24 h. The cells were pretreated with 0 or 5 mg/mL HA for 1 h, followed by incubation with MoS2–SS–HA–RB ([RB] = 40 μg/mL) for another 2 h. After the cells were stained with Hoechst 33258, fluorescence images of the cells were acquired via a confocal microscopy (TCS SP8, Leica) in the two channels relevant to Hoechst 33258 (405 nm) and RB (550 nm).
For flow cytometry analyses, A549 and HELF cells preseeded in 6-well plates at densities of 3 × 105 and 4 × 105 cells/well, respectively, were treated with 0 or 5 mg/mL HA for 1 h, washed with PBS, and then incubated with MoS2–SS–HA–RB ([RB] = 40 μg/mL) for another 2 h. After being rinsed with PBS, trypsinized, and centrifuged, the collected cells were analyzed via a flow cytometry (FACSAriaIII, BD).
Intracellular cargo release
A549 cells were seeded in confocal dishes at a density of 3 × 105 cells/dish and incubated for 24 h. The cells were treated with 0 or 10 mM glutathione reduced ethyl ester (GSH-OEt) for 2 h. Fresh cell medium containing MoS2–SS–HA–RB ([RB] = 40 μg/mL) was added to the dishes and replaced the original medium. After incubation for 2 h, the cells were transferred into fresh complete medium, either not irradiated or irradiated with an 808-nm laser (1 W/cm2) for 10 min, and then imaged via confocal microscopy.
The intracellular cargo release mechanism was also characterized by flow cytometry analyses. Briefly, A549 cells preseeded in 6-well plates at a density of 3 × 105 cells/well were treated with 0 or 10 mM GSH-OE for 2 h, washed with PBS, and then incubated with MoS2–SS–HA–RB ([RB] = 40 μg/mL) for another 2 h. Excess nanosheets were removed, and fresh complete medium was added to the wells. After NIR irradiation (1 W/cm2 for 10 min), the cells were harvested with trypsin and resuspended in PBS buffer for flow cytometry analyses.
Cytotoxicity of MoS2–SS–HA–CPT in vitro
The cytotoxicity of MoS2–SS–HA–CPT in vitro was evaluated using MTT assays. Typically, A549 cells preseeded into 96-well plates at 5 × 103/well were incubated with cell medium containing 0 or 10 mM GSH-OE for 2 h. The cells were then washed with PBS and treated with MoS2–SS–HA–CPT or free CPT (dissolved in DMSO and diluted in cell medium) at CPT concentrations of 3.15, 6.3, 12.5, 25, and 50 μg/mL for 2 h. After this treatment, excess CPT and MoS2–SS–HA–CPT were removed by extensive washing with PBS, and fresh cell medium was used to culture the cells for another 48 h prior to the MTT assay to determine cell viability.
In vitro synergistic chemo-photothermal therapy
A549 cells preseeded into 96-well plates at 5 × 103/well were divided into five groups as follows: (i) culture medium as a control, (ii) culture medium + NIR, (iii) CPT + NIR, (iv) MoS2–SS–HA + NIR, and (v) MoS2–SS–HA–CPT ([CPT] = 20 μg/mL, [MoS2–SS–HA] = 100 μg/mL) + NIR. After treatment with 0 or 10 mM GSH-OEt for 2 h, the cells were incubated with cell medium containing the corresponding formulations. After 2 h, fresh cell medium was added to the dishes and replaced the original medium. The cells in groups ii, iii, iv, and v were irradiated with an 808-nm laser for 10 min (1 W/cm2). Afterwards, all of the cells were further incubated for 48 h, and the MTT assay was carried out to measure cell viability. Meanwhile, microscopic observation of the morphologies of cells after various treatments was achieved using an inverted phase-contrast microscope (BDS300, Optec).
Tissue biodistribution of MoS2–SS–HA–CPT
The tissue biodistribution of MoS2–SS–HA–CPT was assessed in lung cancer cell-bearing nude mice. For establishment of the tumor model, A549 cells (5 × 106) suspended in 50 μL PBS were subcutaneously injected into the forelimb of female BALB/C nude mice. When the mean tumor volume reached approximately 200 mm3, the mice were randomly divided into five groups (n = 3 per group) and intravenously administered MoS2–SS–HA–CPT (1.2 mg/kg) + HA (50 mg/kg) or MoS2–SS–HA–CPT. At set time points (6, 12, 24 and 48 h), the mice were sacrificed, and tissue samples (heart, liver, spleen, lung, kidney and tumor) were collected and weighed. The amount of MoS2–SS–HA–CPT in the major organs and tumor was quantified according to a method reported by Liu et al. . After the tissue samples were digested by aqua regia, the Mo amount in the major organs and tumors was measured via inductively coupled plasma-atomic emission spectrometry (ICP-AES).
In vivo synergistic chemo-photothermal therapy
The tumor model was established as described in “Tissue biodistribution of MoS2–SS–HA–CPT” section. When the tumor volume increased to approximately 80 mm3, the nude mice were randomly divided into 5 groups (n = 5/group) and intravenously injected with 200 μL of (i) PBS containing 1% DMSO (v/v) as a control, (ii) CPT (dissolved in the aforementioned PBS), (iii) MoS2–SS–HA + NIR, (iv) MoS2–SS–HA–CPT, or (v) MoS2–SS–HA–CPT ([CPT] = 0.2 mg/kg, [MoS2–SS–HA] = 1 mg/kg) + NIR. After 24 h, groups (i), (ii), (iii) and (v) were subjected to NIR irradiation under an 808-nm laser at 1 W/cm2 for 10 min. During the irradiation, a FLIR thermal camera was used to monitor the real-time temperature changes in tumors. The body weight and tumor size of each mouse were measured and recorded every 3 days. The tumor volume was calculated as follows: V (volume, mm3) = length (mm) × width2 (mm2)/2. The tumor growth inhibition ratio (R) was calculated as follows: R (%) = 100% × (Vcontrol group − Vexperiment group)/Vcontrol group. After 24 days, all of the mice were sacrificed, and the major organs were collected for hematoxylin–eosin (HE) staining.
Quantitative data are presented as the mean ± SD of at last three independent experiments. Statistical significance was assessed via Student’s t-test or one-way ANOVA using the GraphPad Prism 5 software. A p-value less than 0.05 was considered significant.
Results and discussion
Preparation and characterization of MoS2–SS–HA nanosheets
MoS2 nanosheets were synthesized from MoS2 crystals using a chemical exfoliation method . In this case, some surface sulfur atoms of MoS2 were lost during exfoliation, forming defects available for binding with sulfur-containing moieties via the formation of disulfide linkages [41, 42]. In the current work, the preparation of redox-sensitive MoS2-based HA-functionalized nanosheets was divided into two steps: first, cystamine was conjugated via EDC/NHS coupling, and DTT was used to generate free thiol groups in the backbone of HA by cleaving the disulfide linkage in the conjugated cystamine moiety; second, the thiolated HA was coupled to the MoS2 nanosheets by forming disulfide bonds. The resulting MoS2–SS–HA nanosheets were characterized by FT-IR spectroscopy. According to the FT-IR analysis (Fig. 1b), compared with HA, HA–SH showed new absorption peaks at 1659 cm−1, 1553 cm−1, and 2526 cm−1 associated with the stretching vibrations of –CO–, –NH–, and –SH bonds, respectively, suggesting successful preparation of sulfhydrylated HA. After conjugation with MoS2, the –SH– band at 2526 cm−1 disappeared; however, several new absorbance peaks characteristic of HA–SH emerged at 1725 cm−1 (C=O stretching of –COOH), 1658 cm−1 (amide I band), 1553 cm−1 (amide II band), 1410 cm−1 (carboxylate symmetric stretching), and 1048 cm−1 (C–O stretching). The data indicated the attachment of HA–SH through the attachment of the thiol moiety to the defects of MoS2 by forming disulfide bonds. The presence of HA on MoS2 was also proven by UV–vis spectroscopy (Additional file 1: Figure S1), and the weight percentage of HA–SH in MoS2–SS–HA was calculated to be 20.5% by TGA (Additional file 1: Figure S2).
The morphology and size-associated properties of MoS2 and MoS2–SS–HA were investigated using AFM and DLS. As shown in the AFM images (Fig. 1c), MoS2 with a flat surface showed a height of ~ 1 nm, consistent with the height of MoS2 samples reported previously, indicating complete exfoliation of multilayered MoS2 to single-layered nanosheets . After HA was grafted onto MoS2, the height of MoS2 increased to ~ 4 nm, suggesting the existence of HA coating. However, the size of MoS2 nanosheets measured by AFM decreased from ~ 420 to ~ 170 nm after HA coating because of the sonication treatment, as also proven by the DLS results (Additional file 1: Figure S3a). Because of the introduction of carboxyl groups from HA–SH, the zeta potential of MoS2 became highly negative (− 43 mV, Additional file 1: Figure S3b).
After confirming the successful preparation of MoS2–SS–HA, we investigated its stability in deionized water, PBS, and cell medium. As shown in Fig. 1d, the MoS2 nanosheets were stable in deionized water with no agglomeration but rapidly aggregated (within 60 min) in PBS and cell medium due to the screening of the electrostatic charge on the MoS2 surface . In contrast, the MoS2–SS–HA nanosheets still dispersed well in deionized water, PBS, and cell medium after storage for 1 week. The high physiological stability provided by HA is critical for the application of MoS2–SS–HA nanosheets in biological fields.
Redox-sensitive MoS2–SS–HA nanosheets
The redox stimuli-responsiveness of MoS2–SS–HA was verified by changes in the size of the nanosheets after exposure to reducing agents (e.g., GSH). As shown in Fig. 2a–c, after 24 h of immersion in 10 μM GSH solutions (deionized water, PBS and cell medium), the MoS2–SS–HA maintained its structural integrity, with no change in nanosheet size. The good stability of MoS2–SS–HA in a physiological environment with a low concentration of a biological reducing agent was expected to decrease the leakage of encapsulated drugs during blood circulation. Upon exposure to PBS with 10 mM GSH, the MoS2–SS–HA exhibited a rapid increase in diameter from ~ 180 to ~ 2670 nm within 60 min (Fig. 2d). This result is attributed to cleavage of the disulfide bonds in the presence of high GSH concentrations and to separation of HA from MoS2, resulting in stacking of the naked MoS2 nanosheets. Furthermore, severe agglomeration occurred after 6 h in PBS due to the accumulation of MoS2. A similar phenomenon was again observed in cell medium with 10 mM GSH (Fig. 2e). By contrast, the average size of MoS2–SS–HA nanosheets in deionized water containing 10 mM GSH decreased from 160 to 105 nm within 1 h (Fig. 2f). These results reveal that the structural integrity of MoS2–SS–HA is maintained during blood circulation in vivo but is disrupted by tumor-associated GSH.
Photothermal performance of MoS2–SS–HA nanosheets
Photothermal therapy of cancer involves conversion of absorbed NIR light into vibrational energy by photothermal agents, which generates heat to induce tumor ablation . Hence, the optical properties of MoS2–SS–HA must be investigated prior to application of MoS2–SS–HA as a photothermal agent for cancer therapy. In this study, we first examined whether the presence of HA affected the strong absorbance of MoS2 in a NIR region (from 700 to 850 nm). As shown in Additional file 1: Figure S1, the UV–vis–NIR spectra of MoS2 revealed that decoration with HA did not alter the NIR absorbance of MoS2. We subsequently investigated the photothermal properties of MoS2–SS–HA by monitoring the temperature variations of aqueous solutions containing MoS2–SS–HA at various concentrations (12.5, 25, 50, 100 μg/mL) under NIR irradiation (1 W/cm2 for 600 s). The temperature of the MoS2–SS–HA solutions increased rapidly during irradiation, with obvious time and concentration dependence, whereas the temperature of the water sample barely changed under the same conditions (Fig. 3a). For example, the highest temperature increment of MoS2–SS–HA solutions at concentrations of 12.5, 25, 50, and 100 μg/mL after NIR irradiation for 600 s was 18.1, 25.5, 33.9, and 50.1 °C, respectively. In contrast, pure water showed only a ~ 3.2 °C increase in temperature under the same irradiation conditions. Next, we measured the photothermal conversion efficiency (ƞ) of the MoS2–SS–HA nanosheets using a method reported previously . Based on the obtained data (Fig. 3b, c), the ƞ value of MoS2–SS–HA nanosheets was determined to be ~ 28.8%, which was much higher than that of widely used photothermal agents, such as gold nanorods (~ 21%) and Cu2−xSe nanosheets (~ 22%) . In addition, we studied the photothermal stability of MoS2–SS–HA nanosheets by recording the temperature changes of the sample with and without laser irradiation for three cycles (Additional file 1: Figure S4) and found that the temperature changes in the three cycles were consistent, indicating excellent photothermal stability of the nanosheets. This strong NIR absorbance, high photothermal conversion efficiency, and excellent photothermal stability make MoS2–SS–HA a highly promising photothermal agent for cancer therapy.
Drug loading and dual-stimuli-responsive drug release
CPT is aromatic and hydrophobic, making it poorly soluble in water, which seriously diminishes its therapeutic efficacy against tumors. To address this problem, many nanosized CPT delivery systems have been developed, including GO, PLGA, and MSNs [46,47,48]. Unfortunately, the MoS2-based CPT delivery system has not been established until now. In this work, for the first time, we employed MoS2-based nanosheets as a carrier for the delivery of CPT. Drug loading was achieved by simply mixing CPT (dissolved in DMSO solution) with MoS2–SS–HA aqueous solution. After removal of unbound CPT via filtration and ultrafiltration, an absorption peak at 365 nm (characteristic of CPT) appeared in the UV–vis spectra of MoS2–SS–HA, offering direct evidence of CPT loading (Fig. 3d). Similar to the previously reported MoS2-PEG/DOX conjugates, the loading of CPT onto MoS2–SS–HA nanosheets was driven by hydrophobic interactions . We then calculated the amount of drug loaded on the basis of the optical density of MoS2–SS–HA at 365 nm before and after drug loading. The CPT loading ratio (the weight ratio of the loaded drug versus MoS2–SS–HA) was determined to be ~ 20.6%, which is comparable to that of GO (20%) and much higher than that of PLGA (5.5%) and MSNs (1%) [46,47,48].
The drug release behaviors of MoS2–SS–HA–CPT was investigated through dialysis in PBS containing DMSO (5% v/v, pH 7.4) with or without external stimuli. A PBS buffer with different concentrations of GSH (10 μM and 10 mM) was used to simulate the extracellular and intracellular environments. As shown in Fig. 3e, less than 8% CPT was released from MoS2–SS–HA–CPT in PBS buffer without GSH over a period of 12 h, and the addition of 10 μM GSH to the medium triggered only a slight increase (~ 1.3%) in drug release over the same incubation time. However, upon exposure of MoS2–SS–HA–CPT to 10 M GSH, the cumulative release percentage of CPT rapidly increased from ~ 9.1 to ~ 22.9%. These results suggested that MoS2–SS–HA–CPT could not only prevent the encapsulated drug from randomly leaking during blood circulation but also trigger drug release at the tumor site based on its redox responsiveness to tumor-relevant GSH. In addition to the evaluation of GSH-induced drug release, we wondered whether MoS2–SS–HA–CPT possessed the same photothermal-triggered drug release property as DOX-loaded MoS2 nanosheets . After initial NIR irradiation, the cumulative release percentage of CPT increased sharply from ~ 4.3 to ~ 13.5% within 10 min, indicating a significantly accelerated drug release process (Fig. 3f). The NIR-light-triggered drug release was ascribed to the accelerated drug molecular motion caused by the generated heat upon NIR irradiation . More importantly, the cumulative drug release percentage under dual stimuli (GSH and NIR light) increased to ~ 48.1% within 12 h, which was 2.11- and 1.93-fold greater than that of GSH or NIR light alone, respectively. These findings reveal that the constructed MoS2 nanosheets with a unique structure can effectively prevent random leakage of the encapsulated drug during blood circulation and accelerate drug release at the tumor site under dual stimuli, thereby producing minimal side effects and maximum therapeutic efficacy.
Biocompatibility of MoS2–SS–HA
Evaluating the biocompatibility of MoS2–SS–HA nanosheets is essential before their applications in biological fields. First, we assessed the blood compatibility of MoS2–SS–HA. After 2 h of incubation with the corresponding formulations, the optical density of all samples at 541 nm was determined by UV–vis spectrophotometry, and the hemolysis rate of MoS2–SS–HA with various concentrations ranging from 25 to 400 μg/mL was calculated according to the formula in “Hemolysis assay” section. As shown in Fig. 4a, no obvious hemolytic effect of MoS2–SS–HA was observed, with a hemolysis rate of less than 5%, demonstrating good blood compatibility of the nanosheets. In addition, we investigated the cytotoxicity of MoS2–SS–HA in vitro. After 48 h of incubation of A549 cells with MoS2–SS–HA at different concentrations, more than 90% of the A549 cells remained alive (Fig. 4b), even when the concentration of nanosheets was as high as 400 μg/mL. Moreover, no observable toxicity of MoS2–SS–HA to HELF cells was observed. The low cytotoxicity and negligible hemolytic effects of MoS2–SS–HA are conducive to their applications in the biomedical field.
Cellular uptake and intracellular drug release
To study the cellular uptake of MoS2–SS–HA and the intracellular drug release kinetics by confocal microscopy and flow cytometry, the fluorescent dye RB was loaded onto MoS2–SS–HA to form fluorescent-labeled MoS2 nanosheets. The UV–vis spectra of MoS2–SS–HA–RB exhibited the characteristic RB peak at 575 nm, suggesting RB loading (Additional file 1: Figure S5).
A549 (HA receptor positive) and HELF (HA receptor negative) cells were incubated with MoS2–SS–HA–RB ([RB] = 40 μg/mL) for 2 h. After the cells were washing with PBS, their fluorescence images were obtained using a confocal microscope. As shown in Fig. 5a, strong RB fluorescence was observed in A549 cells, whereas HELF cells showed very weak fluorescence intensity, indicating that MoS2–SS–HA–RB could be transported effectively into A549 cells. To further explore the cellular uptake mechanism of HA-grafted MoS2 nanosheets, A549 cells were pretreated with excess HA for 1 h before incubation with MoS2–SS–HA–RB. As expected, a very weak fluorescence signal was detected in the HA-pretreated A549 cells, suggesting that the cellular uptake of MoS2–SS–HA–RB was blocked by excess HA. These results suggested that the uptake of HA-grafted MoS2 nanosheets by HA-receptor overexpressed cancer cells were much more efficient than that by non-cancer cells with low expression level of HA receptor, which could facilitate the accumulation of CPT delivered by the nanosheets at the tumor site.
Inspired by the results in Fig. 3e, f, we wondered whether GSH and NIR light could achieve the controlled release of the cargo inside the cells. The RB loading process caused the fluorescence quenching (Additional file 1: Figure S6), possibly due to strong interactions between the RB and MoS2 nanosheets . From another perspective, recovery of the detected RB fluorescence may act as an indication of cargo release from the nanosheets. In this experiment, to simulate the intracellular environment, GSH-OEt, GSH-reduced ethyl ester with no cytotoxicity (Additional file 1: Figure S7), was used to increase the cellular GSH level. A549 cells were pretreated with 0 or 10 mM GSH-OEt for 2 h, followed by incubation with fresh culture medium containing MoS2–SS–HA–RB ([RB] = 40 μg/mL) for another 2 h. After removal of excess MoS2–SS–HA–RB through extensive washing with PBS, the cells were irradiated with an 808-nm laser (1 W/cm2) for 10 min and imaged via confocal microscopy. As shown in Fig. 5b, compared with cells not exposed to any stimulus, the MoS2–SS–HA–RB-incubated cells showed obviously enhanced RB fluorescence after pretreatment with GSH-OEt or NIR irradiation alone, suggesting that both GSH and NIR light could trigger the release of cargo from internalized nanosheets. The GSH-triggered intracellular cargo release was associated with the separation of the HA shell from the surface of MoS2 based on GSH-responsive disulfide linkage degradation. For NIR light-responsive cargo release, the MoS2-based generated heat upon NIR irradiation accelerated the molecular motion of the loaded cargo, resulting in rapid cargo release insides the cells. More importantly, the group of cells pretreated with GSH-OEt (10 mM) and NIR irradiation (1 W/cm2 for 10 min) showed the strongest RB fluorescence among the four groups, indicating that dual-stimuli-triggered intracellular cargo release was much faster than single-triggered release with only GSH or NIR irradiation.
We also studied the cellular uptake of HA-grafted MoS2 nanosheets and the release behaviors of cargo from the internalized nanosheets by flow cytometry. As expected, the flow cytometry data (Fig. 5c, d), consistent with the confocal imaging data, further suggested the cellular uptake of HA-grafted MoS2 through HA-receptor-mediated endocytosis and the rapid intracellular cargo release in response to dual stimuli.
In vitro chemotherapy, photothermal therapy, and chemo-photothermal treatments
The target-specific binding of HA-grafted MoS2 to cancer cells along with dual-stimuli-responsive drug release encouraged us to evaluate the antitumor effect of MoS2–SS–HA–CPT in vitro. First, A549 cells were treated with MoS2–SS–HA–CPT at various CPT concentrations for 2 h, washed twice with PBS, and incubated with fresh medium for another 48 h. After these treatments, the cell viability was determined using the MTT assay. As shown in Fig. 6a, both free CPT and MoS2–SS–HA–CPT were cytotoxic in a dose-dependent manner. Notably, MoS2–SS–HA–CPT exhibited higher cytotoxicity than free CPT at the same CPT concentration, possibly due to HA-targeting-enhanced cellular uptake of CPT delivered by those nanosheets. When MoS2–SS–HA–CPT was incubated with GSH-OEt-pretreated cells, the cytotoxicity was significantly enhanced at the tested CPT concentrations because of the rapid intracellular drug release in the presence of high GSH levels. By contrast, the toxicity of free CPT to A549 cells was not affected by the addition of GSH (Additional file 1: Figure S8).
Next, we evaluated the antitumor effect of the combined MoS2-induced photothermal ablation and CPT-mediated DNA damage. In this experiment, GSH-OEt-treated and non-GSH-OEt-treated A549 cells were incubated with free CPT, MoS2–SS–HA, or MoS2–SS–HA–CPT ([CPT] = 20 μg/mL, [MoS2–SS–HA] = 100 μg/mL). After 2 h of incubation, the cells were washed with PBS, transferred into fresh cell medium, and then irradiated with an 808-nm laser (1 W/cm2) for 10 min. The cell viability was determined after incubation for another 48 h. As shown in Fig. 6b, the cells treated with irradiation alone remained healthy, with ~ 93.5% cells alive. However, the viability of cells treated with MoS2–SS–HA–CPT was sharply reduced to ~ 13.4% after NIR irradiation. This result was attributed to the following reasons: first, the MoS2-based generated heat upon laser irradiation caused photothermal ablation of the cells; second, the heat accelerated the release of drug from the nanosheets, resulting in an enhanced chemotherapeutic effect. The low cell viability also suggested that synergetic chemo-photothermal therapy was more efficient in inhibiting cell proliferation than photothermal therapy (~ 44.2%) or chemotherapy (~ 55.4%) alone. When the cells were pretreated with 10 mM GSH-OEt, MoS2–SS–HA–CPT offered the strongest cancer-cell-killing effect under NIR irradiation, with only ~ 7% cells alive, because GSH further triggered drug release. Additionally, an inverted phase-contrast microscope was used to record the changes in cell morphology after various treatments. As expected, the morphologies of cells treated with free CPT, MoS2–SS–HA–CPT, MoS2–SS–HA–CPT + 10 mM GSH-OEt, and MoS2–SS–HA + NIR showed partial destruction, and the morphologies of cells treated with 10 mM GSH-OEt + MoS2–SS–HA–CPT + NIR were totally destroyed (Fig. 6c). These results suggest that MoS2–SS–HA–CPT can effectively suppress cancer cell proliferation under dual stimuli based on synergetic chemo-photothermal therapy.
Biodistribution of MoS2–SS–HA–CPT in vivo
Tissue biodistribution of MoS2–SS–HA–CPT following intravenous administration was assessed by measuring the amount of Mo in major organs (liver, spleen, lung, heart, and kidney) and tumors. At designated times, mice were sacrificed, and major tissues were sliced and digested for analysis by ICP-AES. As shown in Fig. 7a, Mo was rapidly distributed into various organs at 6 h post-i.v. injection but mostly accumulated in the liver and spleen because Kupffer cells and spleen macrophages are responsible for clearing the invaders . The amount of Mo in tissues reached maximum values at 24 h and decreased at later times, mainly because of the gradual clearance of MoS2-based nanosheets in vivo. Liu et al. reported that MoS2 within the physiological environment could be oxidized and transformed into water-soluble Mo(VI) oxide species (e.g., MoO42−), which are then readily excreted from the mouse body via both renal and fecal pathways, not resulting in massive accumulation of Mo in vivo . The residual Mo with a very low concentration not only did not cause side effects in vivo but also contributed to the synthesis of several enzymes in cells because Mo is an essential trace element for these enzymes . To verify the tumor-targeting capacity of HA-grafted MoS2, free HA (50 mg/kg) was intravenously injected before administration of MoS2–SS–HA–CPT. We found that the Mo level in the tumors of mice treated with HA + MoS2–SS–HA–CPT was lower than that in tumors of mice treated with the nanosheets alone (Fig. 7b). In particular, 6, 12 and 24 h after intravenous injection, the Mo levels in the tumors of the MoS2–SS–HA–CPT group were 1.66-, 2.06-, and 2.43-fold higher than those in the MoS2–SS–HA–CPT + HA group, indicating the key role of HA in facilitating the accumulation of MoS2–SS–HA–CPT at the tumor site.
In vivo chemotherapy, photothermal therapy, and chemo-photothermal treatments
The in vivo therapeutic efficiency of MoS2–SS–HA–CPT was assessed in A549 lung-cancer-cell-bearing mice. In this experiment, mice with a tumor volume of ~ 80 mm3 were randomly divided into five groups with five mice per group: (i) PBS control group, (ii) CPT group, (iii) MoS2–SS–HA–CPT group, (iv) MoS2–SS–HA + NIR group, and (v) MoS2–SS–HA–CPT + NIR group. At 24 h after intravenous injection of the corresponding formulations, the tumors of the control, CPT, MoS2–SS–HA + NIR, and MoS2–SS–HA–CPT + NIR groups were irradiated with an 808-nm laser at 1 W/cm2 for 10 min. An IR thermal camera was used to record thermal images of the mice (Fig. 8a) and monitor the temperature changes in tumors (Fig. 8b) during irradiation. For the control and CPT groups, the temperature in the tumor site increased to ~ 36.1 °C after 10 min of irradiation. By contrast, rapid temperature elevation in the tumors in the MoS2–SS–HA + NIR and MoS2–SS–HA–CPT + NIR groups was observed, mainly because of the targeted accumulation of HA-grafted MoS2 nanosheets in tumors and the high photothermal conversion efficiency of MoS2-based nanosheets. More importantly, the high temperature (~ 52 °C) reached after 3 min of NIR irradiation remained nearly constant during the next 7 min of irradiation, which could directly induce ablation of the tumor as well as accelerate drug release from MoS2–SS–HA–CPT . During various 24-day treatments, the body weight and tumor volume of each group were recorded every 3 days. As shown in Fig. 8c, no obvious body weight loss was observed during the treatment with MoS2–SS–HA–CPT, suggesting the negligible side effects of the nanosheets in vivo. The tumor volume data in Fig. 8d, e showed that these formulations (CPT, MoS2–SS–HA–CPT, MoS2–SS–HA + NIR, and MoS2–SS–HA–CPT + NIR) could inhibit tumor growth. Compared with free CPT, MoS2–SS–HA–CPT showed a stronger antitumor effect, possibly due to the tumor-targeting capacity of the nanosheets and redox-responsive drug release. More importantly, after 10 min of continuous irradiation, the MoS2–SS–HA–CPT-treated mice exhibited the lowest tumor volume growth among the groups, and the tumor growth inhibition ratio of the nanosheets was determined to be as high as ~ 89.4%, which is 1.64-fold greater than that of our previously established GO-based HA-grafted gefitinib-loaded nanosheets with redox-responsive drug release , suggesting the excellent antitumor effect of MoS2–SS–HA–CPT under NIR irradiation. This result was ascribed to the MoS2-generated hyperthermia upon NIR irradiation that not only further facilitated the release of CPT and enhanced the chemotherapeutic efficiency of MoS2–SS–HA–CPT but also induced photothermal ablation of the tumor, enabling synergistic chemo-photothermal therapy and effectively inhibiting tumor growth in vivo. After 24 days, all of the mice were sacrificed and the tumors were collected, as shown in Fig. 8f. After the tumors from each group were weighed, we found that the mean tumor weight in the MoS2–SS–HA–CPT + NIR group was the lowest among the five groups (Fig. 8g), further indicating that MoS2–SS–HA–CPT could effectively inhibit tumor growth under NIR irradiation. Finally, the major organs of groups (i) and (v) were excised for histological analysis. No obvious organ damage was observed (Fig. 8h), preliminarily suggesting the safety of these nanosheets in vivo at the tested dose. As a result, the excellent antitumor effect of MoS2–SS–HA–CPT, without obvious side effects or organ damage, may considerably promote their future application for treatment of cancer.
In summary, MoS2 nanosheets decorated with HA were developed as a carrier for targeted delivery of the anticancer drug CPT. Grafting of HA onto the surface of MoS2 via a disulfide linkage not only enhanced the stability of MoS2 nanosheets in a physiological environment but also facilitated release of the encapsulated drug through a GSH-mediated redox response. Moreover, the MoS2-based generated heat upon NIR irradiation further triggered the release of drug from MoS2–SS–HA–CPT and induced photothermal ablation of tumors. Confocal fluorescence images and flow cytometry data together suggested the efficient uptake of HA-grafted MoS2 nanosheets by A549 cells via HA-receptor-mediated endocytosis and the rapid intracellular drug release in response to dual stimuli (GSH and NIR light). Compared with other treatment groups, MoS2–SS–HA–CPT upon dual stimuli more effectively suppressed cell proliferation in vitro and inhibited tumor growth in vivo. The as-prepared MoS2–SS–HA–CPT with a strong targeting ability, dual-stimuli-responsive drug release, and synergistic cancer therapeutic efficiency may provide a new strategy for cancer therapy.
Availability of data and materials
All data generated or analyzed during this study are included in this article and its additional file.
Jang B, Kwon H, Katila P, Lee SJ, Lee H. Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. Adv Drug Deliv Rev. 2016;98:113–33.
Zhou L, Wang H, Li Y. Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance. Theranostics. 2018;8:1059–74.
Kang H, Gravier J, Bao K, Wada H, Lee JH, Baek Y, El Fakhri G, Gioux S, Rubin BP, Coll JL, Choi HS. Renal clearable organic nanocarriers for bioimaging and drug delivery. Adv Mater. 2016;28:8162–8.
Huang W, Chen L, Kang L, Jin M, Sun P, Xin X, Gao Z, Bae YH. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs. Adv Drug Deliv Rev. 2017;115:82–97.
Zheng Y, Su C, Zhao L, Shi Y. Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy. J Nanobiotechnol. 2017;15:28.
Chen Y, Tezcan O, Li D, Beztsinna N, Lou B, Etrych T, Ulbrich K, Metselaar JM, Lammers T, Hennink WE. Overcoming multidrug resistance using folate receptor-targeted and pH-responsive polymeric nanogels containing covalently entrapped doxorubicin. Nanoscale. 2017;9:10404–19.
Lei Y, Hamada Y, Li J, Cong L, Wang N, Li Y, Zheng W, Jiang X. Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression. J Control Release. 2016;232:131–42.
Zeng X, Liu G, Tao W, Ma Y, Zhang X, He F, Pan J, Mei L, Pan G. A drug-self-gated mesoporous antitumor nanoplatform based on pH-sensitive dynamic covalent bond. Adv Funct Mater. 2017;27:1605985.
An X, Zhu A, Luo H, Ke H, Chen H, Zhao Y. Rational design of multi-stimuli-responsive nanoparticles for precise cancer therapy. ACS Nano. 2016;10:5947–58.
Tu X, Wang L, Cao Y, Ma Y, Shen H, Zhang M, Zhang Z. Efficient cancer ablation by combined photothermal and enhanced chemo-therapy based on carbon nanoparticles/doxorubicin@ SiO2 nanocomposites. Carbon. 2016;97:35–44.
Du C, Qian J, Zhou L, Su Y, Zhang R, Dong CM. Biopolymer-drug conjugate nanotheranostics for multimodal imaging-guided synergistic cancer photothermal-chemotherapy. ACS Appl Mater Interfaces. 2017;9:31576–88.
Sun C, Wen L, Zeng J, Wang Y, Sun Q, Deng L, Zhao C, Li Z. One-pot solventless preparation of PEGylated black phosphorus nanoparticles for photoacoustic imaging and photothermal therapy of cancer. Biomaterials. 2016;91:81–9.
Liu Y, Yang M, Zhang J, Zhi X, Li C, Zhang C, Pan F, Wang K, Yang Y, Martinez de la Fuentea J, Cui D. Human induced pluripotent stem cells for tumor targeted delivery of gold nanorods and enhanced photothermal therapy. ACS Nano. 2016;10:2375–85.
Meng Z, Wei F, Wang R, Xia M, Chen Z, Wang H, Zhu M. NIR-laser-switched in vivo smart nanocapsules for synergic photothermal and chemotherapy of tumors. Adv Mater. 2016;28:245–53.
Zhang M, Wang W, Wu F, Yuan P, Chi C, Zhou N. Magnetic and fluorescent carbon nanotubes for dual modal imaging and photothermal and chemo-therapy of cancer cells in living mice. Carbon. 2017;123:70–83.
Chen L, Zhong X, Yi X, Huang M, Ning P, Liu T, Ge C, Chai Z, Liu Z, Yang K. Radionuclide 131 I labeled reduced graphene oxide for nuclear imaging guided combined radio-and photothermal therapy of cancer. Biomaterials. 2015;66:21–8.
Voiry D, Fullon R, Yang J, e Silva CdCC, Kappera R, Bozkurt I, Kaplan D, Lagos MJ, Batson PE, Gupta G. The role of electronic coupling between substrate and 2D MoS2 nanosheets in electrocatalytic production of hydrogen. Nat Mater. 2016;15:1003.
Ye Y, Xiao J, Wang H, Ye Z, Zhu H, Zhao M, Wang Y, Zhao J, Yin X, Zhang X. Electrical generation and control of the valley carriers in a monolayer transition metal dichalcogenide. Nat Nanotechnol. 2016;11:598–602.
Yang G, Zhu C, Du D, Zhu J, Lin Y. Graphene-like two-dimensional layered nanomaterials: applications in biosensors and nanomedicine. Nanoscale. 2015;7:14217–31.
Chou SS, Kaehr B, Kim J, Foley BM, De M, Hopkins PE, Huang J, Brinker CJ, Dravid VP. Chemically exfoliated MoS2 as near-infrared photothermal agents. Angew Chem Int Ed Engl. 2013;52:4160–4.
Liu T, Wang C, Gu X, Gong H, Cheng L, Shi X, Feng L, Sun B, Liu Z. Drug delivery with PEGylated MoS2 nanosheets for combined photothermal and chemotherapy of cancer. Adv Mater. 2014;26:3433–40.
Liu T, Shi S, Liang C, Shen S, Cheng L, Wang C, Song X, Goel S, Barnhart TE, Cai W. Iron oxide decorated MoS2 nanosheets with double PEGylation for chelator-free radiolabeling and multimodal imaging guided photothermal therapy. ACS Nano. 2015;9:950–60.
Wang S, Chen Y, Li X, Gao W, Zhang L, Liu J, Zheng Y, Chen H, Shi J. Injectable 2D MoS2-integrated drug delivering implant for highly efficient NIR-triggered synergistic tumor hyperthermia. Adv Mater. 2015;27:7117–22.
Yu J, Yin W, Zheng X, Tian G, Zhang X, Bao T, Dong X, Wang Z, Gu Z, Ma X. Smart MoS2/Fe3O4 nanotheranostic for magnetically targeted photothermal therapy guided by magnetic resonance/photoacoustic imaging. Theranostics. 2015;5:931.
Liu T, Chao Y, Gao M, Liang C, Chen Q, Song G, Cheng L, Liu Z. Ultra-small MoS2 nanodots with rapid body clearance for photothermal cancer therapy. Nano Res. 2016;9:3003–17.
Yin W, Yu J, Lv F, Yan L, Zheng LR, Gu Z, Zhao Y. Functionalized nano-MoS2 with peroxidase catalytic and near-infrared photothermal activities for safe and synergetic wound antibacterial applications. ACS Nano. 2016;10:11000–11.
Xu C, Teng Z, Zhang Y, Yuwen L, Zhang Q, Su X, Dang M, Tian Y, Tao J, Bao L, et al. Flexible MoS2-embedded human serum albumin hollow nanocapsules with long circulation times and high targeting ability for efficient tumor ablation. Adv Funct Mater. 2018;28:1804081.
Fu C, Tan L, Ren X, Wu Q, Shao H, Ren J, Zhao Y, Meng X. Interlayer expansion of 2D MoS2 nanosheets for highly improved photothermal therapy of tumors in vitro and in vivo. Chem Commun (Camb). 2018;54:13989–92.
Yin W, Yan L, Yu J, Tian G, Zhou L, Zheng X, Zhang X, Yong Y, Li J, Gu Z. High-throughput synthesis of single-layer MoS2 nanosheets as a near-infrared photothermal-triggered drug delivery for effective cancer therapy. ACS Nano. 2014;8:6922–33.
Dicker KT, Gurski LA, Pradhan-Bhatt S, Witt RL, Farach-Carson MC, Jia X. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater. 2014;10:1558–70.
Zhong Y, Goltsche K, Cheng L, Xie F, Meng F, Deng C, Zhong Z, Haag R. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials. 2016;84:250–61.
Dosio F, Arpicco S, Stella B, Fattal E. Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev. 2016;97:204–36.
Dong X, Yin W, Zhang X, Zhu S, He X, Yu J, Xie J, Guo Z, Yan L, Liu X, et al. Intelligent MoS2 nanotheranostic for targeted and enzyme-/pH-/NIR-responsive drug delivery to overcome cancer chemotherapy resistance guided by PET imaging. ACS Appl Mater Interfaces. 2018;10:4271–84.
Yin T, Liu J, Zhao Z, Zhao Y, Dong L, Yang M, Zhou J, Huo M. Redox sensitive hyaluronic acid-decorated graphene oxide for photothermally controlled tumor-cytoplasm-selective rapid drug delivery. Adv Func Mater. 2017;27:1604620.
Zhao Q, Liu J, Zhu W, Sun C, Di D, Zhang Y, Wang P, Wang Z, Wang S. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells. Acta Biomater. 2015;23:147–56.
Wang Y, Zhang XY, Luo YL, Xu F, Chen YS, Su YY. Dual stimuli-responsive Fe3O4 graft poly(acrylic acid)-block-poly(2-methacryloyloxyethyl ferrocenecarboxylate) copolymer micromicelles: surface RAFT synthesis, self-assembly and drug release applications. J Nanobiotechnol. 2017;15:76.
Yin S, Huai J, Chen X, Yang Y, Zhang X, Gan Y, Wang G, Gu X, Li J. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater. 2015;26:274–85.
Zhou Y, Wen H, Gu L, Fu J, Guo J, Du L, Zhou X, Yu X, Huang Y, Wang H. Aminoglucose-functionalized, redox-responsive polymer nanomicelles for overcoming chemoresistance in lung cancer cells. J Nanobiotechnol. 2017;15:87.
Lee H, Mok H, Lee S, Oh YK, Park TG. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release. 2007;119:245–52.
Joensen P, Frindt R, Morrison SR. Single-layer MoS2. Mater Res Bull. 1986;21:457–61.
Chou SS, De M, Kim J, Byun S, Dykstra C, Yu J, Huang J, Dravid VP. Ligand conjugation of chemically exfoliated MoS2. J Am Chem Soc. 2013;135:4584–7.
Kim J, Kim H, Kim WJ. Single-layered MoS2-PEI-PEG nanocomposite-mediated gene delivery controlled by photo and redox stimuli. Small. 2016;12:1184–92.
Li BL, Zou HL, Lu L, Yang Y, Lei JL, Luo HQ, Li NB. Size-dependent optical absorption of layered MoS2 and DNA oligonucleotides induced dispersion behavior for label-free detection of single-nucleotide polymorphism. Adv Funct Mater. 2015;25:3541–50.
Yu X, Yang K, Chen X, Li W. Black hollow silicon oxide nanoparticles as highly efficient photothermal agents in the second near-infrared window for in vivo cancer therapy. Biomaterials. 2017;143:120–9.
Li W, Rong P, Yang K, Huang P, Sun K, Chen X. Semimetal nanomaterials of antimony as highly efficient agent for photoacoustic imaging and photothermal therapy. Biomaterials. 2015;45:18–26.
Bao H, Pan Y, Ping Y, Sahoo NG, Wu T, Li L, Li J, Gan LH. Chitosan-functionalized graphene oxide as a nanocarrier for drug and gene delivery. Small. 2011;7:1569–78.
Zhang K, Li P, He Y, Bo X, Li X, Li D, Chen H, Xu H. Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF & chemotherapy synergistic tumor treatment. Biomaterials. 2016;99:34–46.
Ma M, Chen H, Chen Y, Zhang K, Wang X, Cui X, Shi J. Hyaluronic acid-conjugated mesoporous silica nanoparticles: excellent colloidal dispersity in physiological fluids and targeting efficacy. J Mater Chem. 2012;22:5615–21.
Ikarashi M, Nakashima H, Kinoshita M, Sato A, Nakashima M, Miyazaki H, Nishiyama K, Yamamoto J, Seki S. Distinct development and functions of resident and recruited liver Kupffer cells/macrophages. J Leukoc Biol. 2013;94:1325–36.
Hao J, Song G, Liu T, Yi X, Yang K, Cheng L, Liu Z. In vivo long-term biodistribution, excretion, and toxicology of PEGylated transition-metal dichalcogenides MS2 (M = Mo, W, Ti) nanosheets. Adv Sci (Weinh). 2017;4:1600160.
Li Z, Liu J, Hu Y, Li Z, Fan X, Sun Y, Besenbacher F, Chen C, Yu M. Biocompatible PEGylated bismuth nanocrystals: “All-in-one” theranostic agent with triple-modal imaging and efficient in vivo photothermal ablation of tumors. Biomaterials. 2017;141:284–95.
Liu J, Zhang D, Lian S, Zheng J, Li B, Li T, Jia L. Redox-responsive hyaluronic acid-functionalized graphene oxide nanosheets for targeted delivery of water-insoluble cancer drugs. Int J Nanomed. 2018;13:7457–72.
This work was supported by the Ministry of Science and Technology of China (2015CB931804) and the National Natural Science Foundation of China (U1505225 and 81773063).
Ethics approval and consent to participate
All animal studies were performed in accordance with animal protocol procedures approved by the Institutional Animal Care and Use Committee (IACUC) of Fuzhou University, which are consistent with the American Association for Laboratory Animal Science (AAALAS) guidelines.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
UV–vis–NIR spectra of MoS2 before and after HA coating. Figure S2. Weight loss curves of MoS2-SS-HA. Figure S3. (a) Size and (b) zeta potential data of MoS2 before and after HA coating. Figure S4. Temperature variation of MoS2-SS-HA suspension (100 μg/mL) over 3 cycles of NIR irradiation (1 W/cm2) and natural cooling. Figure S5. UV–vis–NIR spectra of MoS2-SS-HA before and after RB loading. Figure S6. Fluorescence spectra of free RB and MoS2-SS-HA-RB at the same RB concentration (6 μg/mL, λex = 550 nm). Figure S7. Viabilities of A549 and HELF cells incubated with cell medium containing various concentrations of GSH-OEt for 48 h. Figure S8. Viabilities of GSH-OEt-treated A549 cells after treatment with various concentrations of free CPT.
About this article
Cite this article
Liu, J., Li, F., Zheng, J. et al. Redox/NIR dual-responsive MoS2 for synergetic chemo-photothermal therapy of cancer. J Nanobiotechnol 17, 78 (2019). https://doi.org/10.1186/s12951-019-0510-2
- MoS2 nanosheets
- Disulfide linkage
- Dual-stimuli-responsive drug release
- Chemo-photothermal therapy